Human trial holds promise for novel cancer vaccines

A small human trial has shown significant promise for developing anti-cancer vaccines and personalised cancer therapies in near future.

In this case, three people with melanoma received vaccines designed to alert the immune system to mutated proteins found in their tumours. Vaccines made from mutated proteins found in tumours bolstered immune responses to cancer.

"It is too soon to say whether the resulting immune response will be enough to rein in tumour growth, but the trial is a crucial proof of concept, " said Ton Schumacher, cancer researcher from the Netherlands Cancer Institute in Amsterdam in a report in the scientific journal Nature.

Mutated proteins produced by cancerous cells can serve as a siren call to immune cells, signalling the presence of a cell that has become, in a sense, "foreign".

Unfortunately, many of these calls are never heard. Some tumours suppress nearby immune responses, and mutated tumour proteins may not be expressed at high enough levels to rally immune cells.

"Researchers have long dreamed of using those mutated proteins to generate a vaccine," says immunologist Beatriz Carreno of Washington University in St. Louis, Missouri.

For this study, the researchers sequenced the tumour genomes in samples taken from three people with melanoma and catalogued the mutated proteins in each sample.

They then chose seven protein fragments per patient for use in the vaccine. White blood cells were taken from each patient and cultured in the laboratory to generate immune cells called dendritic cells.

These cells were then exposed to the protein fragments, allowed to mature in the laboratory and then infused into the patients. By then, the dendritic cells had taken up the protein fragments, and were able to present them to immune cells in the body.

The result: immune cells trained to target the mutated proteins produced by the tumour. Such immune cells were evident in the patients' blood two weeks after vaccination.

According to Carreno, the approach could also work in other cancers that contain a lot of mutations, such as lung, colon and bladder tumours.